^{2nd Middle East Pharmacy and Pharmaceutical Conference}

IMPUCT is the development of technology for the manufacture of polymeric matrix implants for extended release of drugs. Hot-melt extrusion was the selected manufacturing process to obtain the implants and the polymers used belong to lactate/glycolate copolymers group as they are biodegradable and because of their plastic and thermal properties. IMPUCT aimed to test its applicability through the development of a prototype implant with a frequency of administration of not less than 14 days, ideally once a month administration, Pre-clinical results showed efficacy and developed analytical methods for determination of “in vitro” biologic activity of the active substance during processing revealed the maintenance of active substance activity. Thus, IMPUCT develops the technology to achieve the necessary requirements so that the production of implants could be, in a subsequent phase, transposed to an industrial scale and that the developed exenatide implant is included in a clinical development program in humans.